ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó |
|
|
|
2014³âµµ Á¦ 100Â÷ ´ëÇÑ»êºÎÀΰúÇÐȸ ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó ¼ö»óÀÚ·Î ¼±Á¤µÇ½ÉÀ» Áø½ÉÀ¸·Î ÃàÇϵ帳´Ï´Ù. |
|
¸ðüžÆÀÇÇÐ
|
- ¼º¸í : Â÷ÇöÈ
- ¼Ò¼Ó : °æºÏÀÇ´ë
- ³í¹®Á¦¸ñ : The upper cutoff values of 50-g glucose challenge test that can omit 100-g glucose tolerance test according to
NDDG and Carpenter and Coustan criteria
|
|
ºÎÀÎÁ¾¾çÇÐ
|
- ¼º¸í : ¹éÀ̼±
- ¼Ò¼Ó : ¼º±Õ°üÀÇ´ë
- ³í¹®Á¦¸ñ : Survival analysis of Revised 2013 FIGO Staging Classification of Epithelial Ovarian Cancer and Comparison with
Previous FIGO Staging Classification
|
|
»ý½Ä³»ºÐºñÇÐ
|
- ¼º¸í : ±è¼ö¹Ì
- ¼Ò¼Ó : °¡Å縯ÀÇ´ë
- ³í¹®Á¦¸ñ : The expression of Mullerian Inhibiting Substance Type II Receptor (MISRII) in Endometrial hyperplasia
|
|
ÀϹݺÎÀΰúÇÐ
|
- ¼º¸í : ÀÌÁö¼±
- ¼Ò¼Ó : ¾ÆÁÖÀÇ´ë
- ³í¹®Á¦¸ñ : Lateral distribution of ovarian endometriomas and postoperative recurrences
|
|